Clarius Group LLC Purchases 1,620 Shares of Johnson & Johnson (NYSE:JNJ)

Clarius Group LLC lifted its position in Johnson & Johnson (NYSE:JNJGet Rating) by 5.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 30,583 shares of the company’s stock after buying an additional 1,620 shares during the period. Johnson & Johnson comprises 0.5% of Clarius Group LLC’s portfolio, making the stock its 26th largest holding. Clarius Group LLC’s holdings in Johnson & Johnson were worth $5,429,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Taylor & Morgan Wealth Management LLC lifted its stake in Johnson & Johnson by 1.6% during the 2nd quarter. Taylor & Morgan Wealth Management LLC now owns 3,580 shares of the company’s stock valued at $635,000 after acquiring an additional 57 shares during the period. Circle Wealth Management LLC lifted its stake in Johnson & Johnson by 0.5% during the 1st quarter. Circle Wealth Management LLC now owns 11,326 shares of the company’s stock valued at $2,007,000 after acquiring an additional 59 shares during the period. Red Wave Investments LLC lifted its stake in Johnson & Johnson by 2.0% during the 2nd quarter. Red Wave Investments LLC now owns 2,986 shares of the company’s stock valued at $530,000 after acquiring an additional 59 shares during the period. Argus Investors Counsel Inc. lifted its stake in Johnson & Johnson by 0.6% during the 2nd quarter. Argus Investors Counsel Inc. now owns 10,936 shares of the company’s stock valued at $1,941,000 after acquiring an additional 61 shares during the period. Finally, Alta Capital Management LLC lifted its stake in Johnson & Johnson by 0.4% during the 2nd quarter. Alta Capital Management LLC now owns 15,824 shares of the company’s stock valued at $2,808,000 after acquiring an additional 61 shares during the period. Institutional investors own 68.59% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on JNJ shares. Atlantic Securities decreased their target price on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a research note on Wednesday, October 19th. Morgan Stanley decreased their target price on shares of Johnson & Johnson from $174.00 to $170.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 19th. Sanford C. Bernstein decreased their target price on shares of Johnson & Johnson from $194.00 to $190.00 in a research note on Wednesday, October 19th. Bank of America decreased their target price on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a research note on Friday, October 14th. Finally, Citigroup reduced their price objective on shares of Johnson & Johnson from $201.00 to $198.00 in a research report on Wednesday, October 5th. Seven analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $181.33.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, CAO Robert J. Decker sold 16,928 shares of the company’s stock in a transaction dated Friday, November 18th. The shares were sold at an average price of $175.00, for a total value of $2,962,400.00. Following the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at $2,707,775. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Johnson & Johnson news, CAO Robert J. Decker sold 16,928 shares of the company’s stock in a transaction dated Friday, November 18th. The shares were sold at an average price of $175.00, for a total value of $2,962,400.00. Following the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at $2,707,775. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Kathryn E. Wengel sold 16,410 shares of the stock in a transaction dated Wednesday, November 9th. The stock was sold at an average price of $173.42, for a total transaction of $2,845,822.20. Following the sale, the executive vice president now directly owns 71,311 shares in the company, valued at approximately $12,366,753.62. The disclosure for this sale can be found here. Insiders have sold 135,723 shares of company stock valued at $23,192,574 over the last 90 days. 0.35% of the stock is owned by insiders.

Johnson & Johnson Trading Up 0.5 %

Shares of JNJ opened at $175.97 on Tuesday. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The firm has a 50-day moving average price of $168.04 and a 200 day moving average price of $171.28. The firm has a market capitalization of $460.07 billion, a P/E ratio of 24.51, a P/E/G ratio of 3.49 and a beta of 0.57.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its earnings results on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, beating analysts’ consensus estimates of $2.49 by $0.06. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The company had revenue of $23.79 billion for the quarter, compared to analysts’ expectations of $23.44 billion. During the same quarter in the prior year, the company posted $2.60 earnings per share. Johnson & Johnson’s revenue for the quarter was up 1.9% compared to the same quarter last year. Sell-side analysts forecast that Johnson & Johnson will post 10.04 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 6th. Shareholders of record on Tuesday, November 22nd will be given a $1.13 dividend. The ex-dividend date of this dividend is Monday, November 21st. This represents a $4.52 dividend on an annualized basis and a yield of 2.57%. Johnson & Johnson’s payout ratio is currently 62.95%.

Johnson & Johnson announced that its Board of Directors has initiated a stock buyback program on Wednesday, September 14th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the company to buy up to 1.2% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s board believes its shares are undervalued.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.